What can the molecular pathologist offer for optimal decision making?

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Richman, S D ^a   Hutchins, G G A ^a   Seymour, M T ^a   Quirke, P ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Advanced; Biomarker; Colorectal; Metastatic; Predictive; Prognostic

Indexed keywords

AMPHIREGULIN; APC PROTEIN; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; THYMIDYLATE SYNTHASE; VASCULOTROPIN;

CHROMOSOME 17P; CHROMOSOME 18Q; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; GENE EXPRESSION PROFILING; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MEDICAL DECISION MAKING; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE; OVERALL SURVIVAL; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 78649337574     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq379     Document Type: Conference Paper

References (78)

1. Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13: 3806-3815.
2. Prenen H, Tejpar S, Van Cutsem E. Impact of molecular markers on treatment selection in advanced colorectal cancer. Eur J Cancer 2009; 45 (Suppl 1): 70-78.
3. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
4. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
5. Walther A, Johnstone E, Swanton C et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009.
6. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130.
7. Peltomaki P. DNA mismatch repair and cancer. Mutat Res 2001; 488: 77-85.
8. Ward R, Meagher A, Tomlinson I et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001; 48: 821-829.
9. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-2087.
10. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618.
11. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 21: 369-373.
12. Lanza G, Gafa R, Santini A et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-2367.
13. Tejpar S, Bosman F, Delorenzi M et al. Microsatellite instability (MSI) in stage II and II colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC3-EORTC 30993-SAKK 60/00 trial). 2009 ASCO Annual Meeting. J Clin Oncol 2009; 27 (Suppl): Abstr 4001.
14. Hutchins G, Southward K, Handley K et al. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. ASCO Annual Meeting 2010 Chicago, IL, USA. Abstr 3517.
15. Jover R, Paya A, Alenda C et al. Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. Am J Clin Pathol 2004; 122: 389-394.
16. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.
17. Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26: 2690-2698.
18. Benatti P, Gafa R, Barana D et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005; 11: 8332-8340.
19. Ward RL, Turner J, Williams R et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2005; 207: 377-384.
20. Wilson PM, Ladner RD, Lenz HJ. Predictive and prognostic markers in colorectal cancer. Gastrointest Cancer Res 2007; 1: 237-246.
21. Roth A, Tejpar S, Yan P et al. Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3-EORTS 40993-SAKK 60-00 trial. 2009 ASCO Meeting. J Clin Oncol 2009; 27 (Suppl): Abstr 4002.
22. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206.
23. Russo A, Bazan V, Lacopetta B et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23: 7518-7528.
24. Munro AJ, Lain S, Lane DP. p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434-444.
25. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-385.
26. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
27. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90: 675-684.
28. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-696.
29. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
30. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-6069.
31. Loughrey MB, Waring PM, Tan A et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6: 301-310.
32. Lavery I, Hammel J, Cowens K et al. Relationship between tumour gene expression and recurrence in an observational cohort of patients with stage II/III colon cancer treated with surgery only: quantative RT-PCR assay of 375 genes in fixed paraffin-embedded (FPE) tissue. ASCO Gastrointest Cancer Symp 2008; Abstr 302.
33. Quasar Collaborative Group, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029.
34. Kerr D, Gray R, Quirke P et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. 2009 ASCO Annual Meeting. J Clin Oncol 2009; 27 (15 Suppl): Abstr 4000.
35. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
36. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-3775.
37. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-1412.
38. Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
39. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002; 28: 27-47.
40. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237.
41. Soong R, Shah N, Salto-Tellez M et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008; 19: 915-919.
42. Vallbohmer D, Yang DY, Kuramochi H et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol 2007; 31: 413-418.
43. Ladner RD, Lynch FJ, Groshen S et al. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 2000; 60: 3493-3503.
44. Sargent DJ, Marsoni S, Thibodeau SN et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II in stage III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. 2008 ASCO Annual Meeting. J Clin Oncol 2008; 26 (Suppl 15): Abstr 4008.
45. Des Guetz G, Uzzan B, Nicolas P et al. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 2009; 29: 1615-1620.
46. Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 2008; 9: 1079-1099.
47. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304.
48. Chua W, Goldstein D, Lee CK et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009; 101: 998-1004.
49. Viguier J, Boige V, Miguel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11: 6212-6217.
50. Slatter JG, Schaaf LJ, Sams JP et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28: 423-433.
51. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
52. Iyer L, Das S, Janisch K et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
53. Palomaki GE, Bradley LA, Douglas MP et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11: 21-34.
54. Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27: 5519-5528.
55. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectaltumor development. N Engl J Med 1988; 319: 525-532.
56. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
57. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
58. Hecht JR, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680.
59. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
60. Edkins S, O'Meara S, Parker A et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006; 5: 928-932.
61. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721.
62. Li WQ, Kawakami K, Ruszkiewicz A et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006; 5: 2.
63. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
64. Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colon cancer. Br J Cancer 2009; 101: 465-472.
65. Samuels Y, Diaz LA, Schmidt-Kittler O et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 561-573.
66. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857.
67. Tol J, Dijkstra JR, Klomp M et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46: 1997-2010.
68. Khambata-Ford S, Christopher R, Garrett NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
69. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
70. Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245.
71. Personeni N, Fieuws S, Piessevaux H et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008; 14: 5869-5876.
72. Cappuzzo F, Finocchiaro G, Rossi E et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19: 717-723.
73. Ooi A, Takehana T, Li X et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17: 895-904.
74. Shia J, Klimstra DS, Li AR et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005; 18: 1350-1356.
75. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
76. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
77. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
78. Maughan NJ, Morris E, Forman D et al. The validity of the Royal College of Pathologists' colorectal cancer minimum dataset within a population. Br J Cancer 2007; 97: 1393-1398.